Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Pharmacovigilance01:19

Pharmacovigilance

886
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
886
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

147
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
147
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

521
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
521

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concurrent Insomnia and Suicidal Ideation and Behavior as Psychiatric Adverse Effects of Clozapine Versus Other Atypical Antipsychotics.

Crisis·2026
Same author

Insomnia Symptoms and Psychopathology in Individuals at Clinical High Risk for Psychosis.

Early intervention in psychiatry·2026
Same author

Herpes simplex virus type 1 isolated from newborns reveals viral diversity between and within patients.

The Journal of infectious diseases·2026
Same author

Increasing the Probability of Comparing Between Traditional Medicare and Medicare Advantage.

Health literacy research and practice·2026
Same author

Clozapine-Induced "Pseudo-Agranulocytosis": Bone Marrow Suppression or Increased Neutrophil Margination?

Schizophrenia bulletin·2026
Same author

Cross-sectional and prospective analysis of the association of the pupillary light reflex with suicidal ideation and suicide attempts.

Journal of psychiatric research·2026

Related Experiment Video

Updated: Jul 17, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

285

The 510(k) Third Party Review Program: Promise and Potential.

Brian J Miller1,2,3, William Blanks4, Brian Yagi5

  • 1Division of Hospital Medicine, Department of Medicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Meyer 8-143, Baltimore, MD, 21287, USA. brian@brianjmillermd.com.

Journal of Medical Systems
|August 29, 2023
PubMed
Summary

The Food and Drug Administration (FDA) 510(k) pathway reviews thousands of medical devices annually. This paper examines the third-party review program

Keywords:
510(k)FDAHealth policyMedical device regulation

More Related Videos

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.4K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K

Related Experiment Videos

Last Updated: Jul 17, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

285
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.4K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K

Area of Science:

  • Medical device regulation
  • Regulatory affairs
  • Health policy

Background:

  • The Food and Drug Administration (FDA) 510(k) pathway approves nearly all medical devices, including those with advanced technologies like AI and ML.
  • Increasing complexity and volume of device applications necessitate efficient review processes.

Purpose of the Study:

  • To review the history and evolution of FDA medical device regulation and the 510(k) pathway.
  • To analyze the 510(k) third-party review program's history and effectiveness.
  • To address stakeholder concerns and propose policy improvements for the third-party review program and overall FDA device regulation.

Main Methods:

  • Historical review of FDA device regulation and the 510(k) pathway.
  • Analysis of the 510(k) third-party review program's development and function.
  • Examination of policy concerns and suggestions from stakeholders, including the FDA.

Main Results:

  • The 510(k) pathway is the primary route for medical device approval, handling 99% of devices.
  • Third-party organizations have assisted in reviewing specific device classes for over 25 years.
  • Increasing complexity of devices, including AI and ML, strains current review capacities.

Conclusions:

  • Streamlining the review of low-to-moderate risk devices can enhance FDA's capacity for complex regulatory challenges.
  • Improving the third-party review program is crucial for efficient FDA medical device regulation.
  • Policy adjustments are needed to optimize the third-party review program and support future regulatory needs.